SPY302.97-0.56 -0.18%
DIA254.35-1.42 -0.56%
IXIC9,368.99-43.37 -0.46%

Why MyoKardia's Stock Is Trading Higher Today

MyoKardia (NASDAQ: MYOK) shares are trading higher on Tuesday. On Monday, the company announced the primary and secondary endpoints for its Phase 3 EXPLORER clinical trials of Mavacamten were met. Also, Citi and Morgan Stanley analysts raised their price targe

Benzinga · 05/12/2020 18:42

MyoKardia (NASDAQ: MYOK) shares are trading higher on Tuesday.

On Monday, the company announced the primary and secondary endpoints for its Phase 3 EXPLORER clinical trials of Mavacamten were met. Also, Citi and Morgan Stanley analysts raised their price targets on Tuesday.

MyoKardia is a U.S.-based clinical-stage biopharmaceutical company which is engaged in discovering, developing and commercializing targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.

MyoKardia shares were trading up 20.36% at $116.62 on Tuesday. The stock has a 52-week high of $117.54 and a 52-week low of $42.65.

Related Links:

Gilead's Remdesivir Reaches Goal In NIAID-Sponsored Coronavirus Trial

Here's How Much Investing $100 In Gilead Sciences Stock Back In 2010 Would Be Worth Today